На этой странице перечислены больницы направления «Хирургическая онкология» (включая Blood Cancer Treatment) в Бангалор, Индия, включая Narayana Health, Manipal Hospitals, Medicover Hospital, Bangalore, Gleneagles Hospitals, Bengaluru и другие.
Спросите нас о «Blood Cancer Treatment» в Бангалор, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 10 аккредитованных больниц (Хирургическая онкология) в Бангалор, Индия
🇮🇳 Narayana Health
🇮🇳 Manipal Hospitals
🇮🇳 Medicover Hospital, Bangalore
🇮🇳 Gleneagles Hospitals, Bengaluru
🇮🇳 Manipal Hospital Malleshwaram (Northside)
🇮🇳 Manipal Hospital, Old Airport Road
🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)
🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)
🇮🇳 Apollo Hospital, Bannerghatta Road
🇮🇳 Fortis Hospital, Bannerghatta Road
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Хирургическая онкология» указано среди её специализаций и она находится в Бангалор, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «blood cancer treatment» в Бангалор, Индия?
Выбор подходящей больницы для «blood cancer treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Хирургическая онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Blood Cancer Treatment»
Blood cancer — encompassing leukemia, lymphoma, and multiple myeloma — requires highly specialized, protocol-driven oncology care that combines chemotherapy, targeted biologics, immunotherapy, and, when indicated, hematopoietic stem cell transplantation (HSCT). Leading cancer centers in India and the UAE report five-year survival rates ranging from 60% to over 85% for many blood cancer subtypes when diagnosed and treated at an advanced, high-volume institution. GAF Healthcare connects international patients to JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, providing end-to-end oncology coordination at a fraction of Western treatment costs.
Clinical Overview
Blood cancers arise from the uncontrolled proliferation of malignant hematopoietic cells within the bone marrow, lymphatic system, or peripheral blood. The three principal categories — leukemia (acute and chronic), lymphoma (Hodgkin and Non-Hodgkin), and multiple myeloma (a plasma cell dyscrasia) — each disrupt normal blood cell production in distinct ways. In leukemia, blasts crowd the marrow, impairing erythropoiesis and thrombopoiesis, leading to anemia, hemorrhagic risk, and severe immunosuppression. Lymphomas originate in lymphoid tissue and can be nodal or extranodal, with Non-Hodgkin lymphoma (NHL) representing over 30 distinct WHO-classified subtypes. Multiple myeloma causes osteolytic bone lesions, hypercalcemia, renal impairment, and recurrent infections via monoclonal immunoglobulin deposition.
Подробнее →Who is a Candidate?
- ELIGIBILITY — DIAGNOSIS-CONFIRMED CASES: Patients with histopathologically confirmed blood cancer (bone marrow biopsy, lymph node biopsy, or trephine biopsy) who require induction chemotherapy, consolidation, maintenance therapy, or hematopoietic stem cell transplantation (autologous or allogeneic HSCT).
- NEWLY DIAGNOSED PATIENTS: Those in need of frontline protocol initiation — including pediatric and adult ALL, AML, CML in chronic/accelerated phase, Hodgkin lymphoma, aggressive and indolent NHL, and newly diagnosed multiple myeloma.
- RELAPSED OR REFRACTORY DISEASE: Patients who have failed one or more prior lines of therapy and require salvage regimens (e.g., R-ICE, R-DHAP, ESHAP for lymphoma; azacitidine or venetoclax-based combinations for AML) or access to CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel) or bispecific T-cell engager therapy.
- STEM CELL TRANSPLANT CANDIDATES: Patients with AML, ALL, CML, MDS, or chemosensitive relapsed lymphoma eligible for myeloablative or reduced-intensity conditioning (RIC) allogeneic HSCT, or autologous HSCT for myeloma and relapsed Hodgkin/NHL.
- REQUIRED DIAGNOSTICS BEFORE TRAVEL: Complete blood count (CBC) with differential and peripheral blood smear; bone marrow aspirate and trephine biopsy with immunohistochemistry (IHC); flow cytometry for immunophenotyping (CD markers panel); cytogenetics — conventional karyotype and FISH; molecular studies — BCR-ABL1 PCR (CML/ALL), FLT3/IDH1/IDH2/NPM1/CEBPA mutation panel (AML), JAK2/CALR/MPL (MPN); NGS panel (hematologic malignancies); serum protein electrophoresis (SPEP), immunofixation, free light chain assay (for myeloma); CT-PET scan (whole body, for lymphoma staging); MRI spine/brain (if CNS involvement suspected); ECHO/echocardiography (pre-anthracycline therapy cardiotoxicity baseline); HLA typing (for allogeneic HSCT candidates and potential sibling donors); Liver function tests, renal function panel, viral serology (HIV, HBV, HCV, CMV, EBV — mandatory pre-transplant).
- +1 more
Treatment Options & Approaches
Chemotherapy Protocols (standard OF CARE)
Induction, consolidation, and maintenance chemotherapy remain the backbone of blood cancer treatment. Regimens are protocol-driven and disease-specific:
- Acute Myeloid Leukemia (AML): Standard '7+3' induction (cytarabine continuous infusion × 7 days + daunorubicin × 3 days); for FLT3-mutated AML, midostaurin is added (RATIFY protocol); IDH1/IDH2-mutated AML is treated with ivosidenib or enasidenib as targeted agents in frontline or relapsed settings. Gemtuzumab ozogamicin (GO) is incorporated in CD33-positive favorable-risk AML.
- Acute Lymphoblastic Leukemia (ALL): HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate/cytarabine; for Philadelphia chromosome-positive ALL (BCR-ABL1+), a second-generation TKI (dasatinib or ponatinib) is mandatory. Blinatumomab (CD19/CD3 bispecific) and inotuzumab ozogamicin (CD22-targeted) are used in MRD-positive or relapsed/refractory ALL, supported by CNS prophylaxis via intrathecal methotrexate/cytarabine.
- Chronic Myeloid Leukemia (CML): First-line tyrosine kinase inhibitor (TKI) therapy — imatinib (generic, affordable), dasatinib, nilotinib, or bosutinib (second-generation); ponatinib or asciminib for T315I-mutant or TKI-resistant disease. Deep molecular response (DMR) monitoring by BCR-ABL1 PCR (IS) is performed at 3, 6, and 12 months to guide TKI continuation, switch, or potential treatment-free remission (TFR) attempt.
- Hodgkin Lymphoma: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for early/intermediate stages; escalated BEACOPP for advanced-stage high-risk disease; brentuximab vedotin (BV) + AVD replacing bleomycin in high-risk advanced HL based on ECHELON-1 data. PET-adapted response evaluation guides escalation or de-escalation.
- Non-Hodgkin Lymphoma (Aggressive — DLBCL): R-CHOP (rituximab + CHOP) remains standard; polatuzumab vedotin-R-CHP (Pola-R-CHP) for high-IPI DLBCL based on POLARIX trial. Relapsed/refractory: R-ICE or R-DHAP salvage → autologous HSCT if chemosensitive; CAR-T (axicabtagene, tisagenlecleucel, lisocabtagene) for third-line and beyond.
- Follicular Lymphoma (Indolent NHL): Rituximab monotherapy or BR (bendamustine + rituximab); obinutuzumab-based combinations; lenalidomide + rituximab (R²); PI3K inhibitors (copanlisib, umbralisib) for relapsed disease.
- Multiple Myeloma: Frontline triplet VRd (bortezomib + lenalidomide + dexamethasone) or DRd (daratumumab + lenalidomide + dexamethasone) per MAIA trial; transplant-eligible patients proceed to autologous HSCT after 4–6 cycles of induction. Novel quadruplet induction (Dara-VRd) is now standard at high-volume centers. Relapsed myeloma: carfilzomib-based triplets, pomalidomide combinations, elotuzumab, isatuximab, selinexor, belantamab mafodotin, or teclistamab (BCMA-CD3 bispecific).
Hematopoietic STEM CELL Transplantation (HSCT)
Подробнее →Восстановление
PHASE 1 — Pre-arrival & Remote Consultation (WEEKS 1–2)
- GAF Healthcare case coordinator collects all existing pathology, biopsy, and molecular reports and submits to the designated hematologist-oncologist in India or UAE for remote multidisciplinary tumor board (MDT) review.
- Second-opinion report, proposed treatment protocol, and itemized cost estimate issued within 5–7 business days.
- Medical visa (India: e-Medical Visa, single or multiple entry) or UAE entry visa facilitated by GAF Healthcare; standard processing 3–5 business days.
- Travel itinerary, airport pickup, and pre-selected hospital-proximate accommodation arranged for patient and one attendant.
PHASE 2 — Arrival & Diagnostic Confirmation (DAYS 1–5)
Подробнее →Возможные риски
Blood cancer treatment carries substantial, protocol-specific risks that must be thoroughly understood before initiating therapy. Induction chemotherapy for AML or ALL induces prolonged profound pancytopenia (absolute neutrophil count <100/μL for 2–4 weeks), creating a critical window for life-threatening infections — bacteremia, invasive fungal infections (Aspergillus, Candida), and viral reactivation (CMV, EBV, VZV). Tumor lysis syndrome (TLS) — characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and acute renal failure — can occur within 12–72 hours of cytotoxic therapy initiation and requires ICU-level prophylactic and reactive management. Anthracycline-based regimens (daunorubicin, doxorubicin) carry cumulative cardiotoxicity risk, measured by serial ECHO assessment of LVEF; patients with pre-existing cardiac dysfunction require dose modification or liposomal formulation substitution. Allogeneic HSCT carries a transplant-related mortality (TRM) of 5–20% depending on donor type (matched sibling lowest, haploidentical highest), conditioning intensity, and patient comorbidity score (HCT-CI — Hematopoietic Cell Transplantation-specific Comorbidity Index). Graft-versus-host disease (GvHD) — both acute (skin, gut, liver, Grades I–IV) and chronic (multiorgan, NIH criteria) — is the primary cause of non-relapse morbidity after allogeneic HSCT; Grade III–IV acute GvHD carries a mortality rate of 30–50%. CAR-T cell therapy is associated with cytokine release syndrome (CRS) in 70–90% of patients (Grades 3–4 in 10–20%) and immune effector cell-associated neurotoxicity syndrome (ICANS, up to 60% of recipients), both requiring expert ICU management and access to tocilizumab and corticosteroids. TKI therapy (imatinib, dasatinib) is generally well tolerated but requires monitoring for pleural effusion (dasatinib-specific), QTc prolongation (nilotinib), and arterial occlusive events. All patients on immunosuppressive regimens require antiviral prophylaxis (acyclovir/valacyclovir), antifungal prophylaxis (fluconazole or posaconazole), and Pneumocystis jirovecii pneumonia (PJP) prophylaxis (trimethoprim-sulfamethoxazole or inhaled pentamidine). International patients must be counseled that treatment timelines are not fixed — disease response, toxicity management, and transplant recovery may extend the in-country stay beyond initial estimates, and flexibility in travel planning is essential.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical coordination for international blood cancer patients traveling to India or the UAE, recognizing that oncology patients require a higher standard of logistical support than routine medical tourists.
Частые вопросы о процедуре «Blood Cancer Treatment»
What is the cost of blood cancer treatment in India vs the UAE?
How long do I need to stay in the country before I am fit to fly home after blood cancer treatment?
What is the success rate of blood cancer treatment at hospitals in India and the UAE?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «blood cancer treatment» в Бангалор, Индия
Найдите лучшие больницы для «blood cancer treatment» в Бангалор, Индия
На этой странице представлено 10 больниц в Бангалор, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Blood Cancer Treatment» в Бангалор, Индия
Сколько больниц направления «Хирургическая онкология» представлено в Бангалор, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Бангалор, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Blood Cancer Treatment» в Бангалор, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.